Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Abhinav Mehta is active.

Publication


Featured researches published by Abhinav Mehta.


Nanomedicine: Nanotechnology, Biology and Medicine | 2009

Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery.

Rishi Paliwal; Shivani Rai; Bhuvaneshwar Vaidya; Kapil Khatri; Amit K. Goyal; Neeraj Mishra; Abhinav Mehta; Suresh P. Vyas

Solid lipid nanoparticles (SLNs) are essentially composed of triglyceride(s) that orient to form a polar core with polar heads oriented toward the aqueous phase, resembling chylomicrons. The composition of such SLNs may alter the course of drug absorption predominantly to and through lymphatic route and regions, presumably following a transcellular path of lipid absorption, especially by enterocytes and polar epithelial cells of the intestine. SLNs were prepared using stearic acid, glycerol monostearate, tristearin, and Compritol 888 ATO by solvent diffusion method using demineralized double-distilled water as the dispersion medium. The SLNs were characterized for shape, size, zeta potential, and percentage drug content and its release. The characterization of SLNs suggests that Compritol 888 ATO-based nanoparticles were heterogeneous with better drug-loading and release characteristics as compared with the other formulations. The selected products were studied for in vivo absorption and hence bioavailability by measure of area under the blood plasma curve plotted as a function of time. Periodic lymphatic concentration of drug following oral administration of respective formulations was also determined by mesenteric duct cannulation and collection of samples. The comparative study conducted on methotrexate (MTX)-bearing SLNs revealed that the formulation based on Compritol 888 ATO could noticeably improve the oral bioavailability of MTX, presumably following SLNs constituting lipid digestion and co-absorption through lymphatic transport and route.


Vaccine | 2008

Surface modified liposomes for nasal delivery of DNA vaccine

Kapil Khatri; Amit K. Goyal; Prem N. Gupta; Neeraj Mishra; Abhinav Mehta; Suresh P. Vyas

The aim of the present work was to investigate the potential utility of glycol chitosan coated liposomes as nasal vaccine delivery vehicle for eliciting viral specific humoral mucosal and cellular immune responses. Plasmid pRc/CMV-HBs(S) encapsulated liposomes were prepared by dehydration-rehydration method and subsequently coated with glycol chitosan by simple incubation method. Liposomes were then characterized for their size, surface charge, entrapment efficiency, and ability to protect encapsulated DNA against nuclease digestion and for their mucoadhesiveness. The liposomes were then administered to mice in order to study their feasibility as nasal vaccine carriers. The developed liposomes possessed +9.8 mV zeta potential and an average vesicle size less than 1 microm and entrapment efficiency of approximately 53%. Following intranasal administration, glycol chitosan coated liposomes elicited humoral mucosal and cellular immune responses that were significant as compared to naked DNA justifying the potential advantage of mucosal vaccination in the production of local antibodies at the sites where pathogens enters the body.


Journal of Controlled Release | 2009

Synthesis, characterization and evaluation of novel triblock copolymer based nanoparticles for vaccine delivery against hepatitis B

Arvind K. Jain; Amit K. Goyal; Prem N. Gupta; Kapil Khatri; Neeraj Mishra; Abhinav Mehta; Sharad Mangal; Suresh P. Vyas

Poly lactic acid (PLA) is one of widely used biodegradable polymer in vaccine delivery. However, the use is restricted due to hydrophobic nature and generation of acidic microenvironment upon its degradation, rendering it unfavorable to the encapsulated antigen. In the present study we have synthesized PEG derivatized block copolymers of PLA for development of nanoparticles encapsulating HBsAg for mucosal vaccination against hepatitis B. The copolymers of compositions AB, ABA and BAB (PLA as A-block and PEG as B-block) were synthesized and characterized by 1H NMR spectroscopy and gel permeation chromatography. Nanoparticles were characterized to determine the effect of copolymer. Among all, BAB produced nanoparticles of smallest size and lowest zeta potential, suggesting highest PEG density on their surface. The in vitro release experiments were performed in PBS (pH7.4). SDS-PAGE analysis confirmed the structural stability and integrity of the released antigen. Results were compared for immunogenicity with plain PLA nanoparticles and conventional alum-HBsAg based vaccine. BAB nanoparticles produced better humoral response as compared to other polymeric nanoparticles. The extent of humoral response obtained in single dose of BAB nanoparticles was comparable to the response produced by alum based vaccine (which received a booster dose). Block copolymeric nanoparticles also produced better sIgA level at all local and distal mucosal sites as compare of PLA nanoparticles, where alum based formulation failed to give any considerable response. Additionally, IgG1 and IgG2a isotype were determined to confirm the T(H)1/T(H)2 mixed immune response. These data demonstrate the potential of BAB nanoparticles as mucosal vaccine delivery system capable of eliciting high and prolonged immune response.


Journal of Pharmacy and Pharmaceutical Sciences | 2008

Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes)

Anshuman Shukla; Kapil Khatri; Prem N. Gupta; Amit K. Goyal; Abhinav Mehta; Suresh P. Vyas

PURPOSE Most of the presently available vaccines including hepatitis B vaccines administered through parenteral route, fail to induce a mucosal antibody response. Therefore, oral immunization appears to be an effective and attractive alternative to parenteral immunization. However, the problem of degradation of antigen in the harsh and hostile environment of the gastrointestinal tract consequently requires larger doses and more frequent dosing of antigen. Furthermore, much larger doses can induce antigen tolerance. Therefore the purpose of the present study was firstly to overcome these problems by the use of bile salt stabilized vesicles (bilosomes) and HBsAg as the model antigen,which could provide both protection to the antigen as well as enable transmucosal uptake and subsequent immunization. Another purpose of this study was to determine the dose that could produce serum antibody titres against hepatitis B via the oral route compared to those following intramuscular immunization. METHODS In the present study bilosomes containing recombinant hepatitis B surface antigen were prepared by a lipid cast film method. HBsAg loaded bilosomeswere characterized in vitro for their shape, size, percent antigen entrapment and stability. Fluorescence microscopy was carried out to confirm the uptake of bilosomes by gut associated lymphoid tissues (GALT). The in vivo part of the study comprised estimation of anti-HBsAg IgG response in serum and anti-HBsAg sIgA in various body secretions using specific ELISA techniques following oral immunization with low dose loaded bilosomes (B1, 10 microg), intermediate dose loaded bilosomes (B2, 20 microg) and high dose loaded bilosomes (B3, 50 microg) in BALB/c mice. RESULTS Fluorescence microscopy suggested that there was an increase in fluorescence intensity following the uptake of bilosomes entrapped FITC-BSA in gut associated lymphoid tissues. The high dose HBsAg bilosomes (B3, 50 microg) produced comparable anti-HBsAg IgG levels in serum to those observed in the case of intramuscular administration of alum adsorbed HBsAg (10 microg). In addition, the bilosomal preparations elicited measurable sIgA in mucosal secretions, where the highest responses were observed with high dose HBsAg bilosomes (B3,50 microg) and as expected, intramuscular administered alum adsorbed HBsAg (10 microg) failed to elicit such responses. CONCLUSIONS HBsAg loaded bilosomes produced both systemic as well as mucosal antibody responses upon oral administration. Furthermore, bilosomes with a five times higher dose upon oral administration produced comparable serum antibody titres to those obtained after intramuscular immunization without the induction of systemic tolerance.


International Journal of Pharmaceutics | 2009

Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate

Rishi Paliwal; Shivani Rai Paliwal; Neeraj Mishra; Abhinav Mehta; Suresh P. Vyas

The aim of the present study was to develop chylomicron mimicking carrier emulsome for oral lymphatic delivery of methotrexate (MTX), an anticancer drug. The compritol 888 ATO (CA) was used as lipid core and soya lecithin (PC) as stabilizer. The optimized emulsome (1:1.2 mole ratio of CA:PC) showed mean particle size of 160.3+/-10.2 nm and with 72.8+/-6.5% drug entrapment efficiency. The differential scanning calorimetric studies revealed a depression in endothermic onset for MTX loaded emulsome. The rapid burst release of the drug was observed in simulated gastric fluid (SGF pH 1.2) with significant increase in particle size of emulsome. However in simulated intestinal fluid (SIF, pH 7.4) a slow and consistent release of the drug was obtained over period of 24 h. Storage stability studies were performed at different temperatures (4+/-1 and 25+/-1 degrees C) for 3 months which suggested that EML remain more stable when stored at refrigerated condition. The in vivo studies were carried out on albino rats and response was estimated collecting blood and lymph both. The pharmacokinetic parameters C(max), t(max) and AUC(0-->12h) after duodenal administration of optimized emulsomal formulation and plain MTX solution were 7.1 and 2.4 microg/mL, 4 and 1 h, 40.45 and 7.2 h microg/mL respectively. The relative bioavailability of MTX was enhanced nearly 5.7 times with optimized EML formulation when compared to plain MTX solution with higher uptake and longer residence time of MTX molecules in lymphatics. Thus, emulsome could be used as lymphotropic carrier for delivery of bioactive(s) and hence for bioavailability enhancement.


Expert Opinion on Therapeutic Patents | 2010

Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers

Neeraj Mishra; Amit K. Goyal; Shailja Tiwari; Rishi Paliwal; Shivani Rai Paliwal; Bhuvaneshwar Vaidya; Sharad Mangal; Madhu Gupta; Devyani Dube; Abhinav Mehta; Suresh P. Vyas

Importance of the field: The mucosal delivery of vaccines provides the basis for induction of humoral, cellular and mucosal immune responses against infectious diseases. The delivery of antigens to and through mucosal barriers always remains challenging due to adverse physiological conditions (pH and enzymes) and biological barriers created by tight epithelial junctions restricting transportation of macromolecules. Mucoadhesive and biodegradable polymers offer numerous advantages in therapeutic delivery of proteins/antigens particularly through the mucosal route by protecting antigens from degradation, increasing concentration of antigen in the vicinity of mucosal tissue for better absorption, extending their residence time in the body and/or targeting them to sites of antigen uptake. Furthermore, antigen can be delivered more effectively to the antigen presenting cells by anchoring the ligand having affinity on the surface of carrier for the receptors present on the mucosal epithelial cells. Areas covered in this review: The present review covers various polymeric carriers, which allow the possibility of modification and manipulation of their properties, thereby, enhancing the effectiveness of mucosal vaccines. This article reviews the recent literature and patents in the field of vaccine delivery using mucoadhesive polymeric carriers. What the reader will gain: The reader will gain insights into various natural polymers, synthetic polymers and ligand derived polymeric carrier systems studied to enhance mucosal immunization. Take home message: Biodegradable polymeric carriers represent a promising approach for mucosal delivery of vaccine.


Journal of Controlled Release | 2009

Development and characterization of novel carrier gel core liposomes based transmission blocking malaria vaccine

Shailja Tiwari; Amit K. Goyal; Neeraj Mishra; Kapil Khatri; Bhuvaneshwar Vaidya; Abhinav Mehta; Yimin Wu; Suresh P. Vyas

The aim of present work was to investigate the potential utility of novel carrier gel core liposomes for intramuscular delivery of transmission blocking malaria antigen Pfs25 and to evaluate the effect of co-administration of vaccine adjuvant CpGODN on immune enhancement of recombinant protein antigen Pfs25. In the present work we have prepared gel core liposomes containing core of biocompatible polymer poly acrylic acid in phospholipid bilayer by reverse phase evaporation method and characterized for various in vitro parameters. In process stability of the encapsulated antigen was evaluated by SDS-PAGE followed by western blotting. The immune stimulating ability was studied by measuring anti-Pfs25 antibody titer in serum of Balb/c mice following intramuscular administration of various formulations. A Significant and perdurable immune responses was obtained after intramuscular administration of gel core liposomes encapsulated Pfs25 as compared to Pfs25 loaded conventional liposomes. Moreover co-administration of CpGODN in liposomes (conventional and gel core) was found to further increase the immunogenicity of vaccine. The result indicates high potential of gel core liposomes for their use as a carrier adjuvant for intramuscular delivery of recombinant antigen Pfs25 based transmission blocking malaria vaccine.


Drug Delivery | 2014

Stimuli-responsive hydrogels in drug delivery and tissue engineering

Nikhil Sood; Ankur Bhardwaj; Shuchi Mehta; Abhinav Mehta

Abstract Hydrogels are the three-dimensional network structures obtained from a class of synthetic or natural polymers which can absorb and retain a significant amount of water. Hydrogels are one of the most studied classes of polymer-based controlled drug release. These have attracted considerable attention in biochemical and biomedical fields because of their characteristics, such as swelling in aqueous medium, biocompatibility, pH and temperature sensitivity or sensitivity towards other stimuli, which can be utilized for their controlled zero-order release. The hydrogels are expected to explore new generation of self-regulated delivery system having a wide array of desirable properties. This review highlights the exciting opportunities and challenges in the area of hydrogels. Here, we review different literatures on stimuli-sensitive hydrogels, such as role of temperature, electric potential, pH and ionic strength to control the release of drug from hydrogels.


Drug Development and Industrial Pharmacy | 2008

Aquasomes—A Nanoparticulate Approach for the Delivery of Antigen

Amit K. Goyal; Kapil Khatri; Neeraj Mishra; Abhinav Mehta; Bhuvaneshwar Vaidya; Shailja Tiwari; Suresh P. Vyas

The development of compound that enhances immune responses to recombinant or synthetic epitopes is of considerable importance in vaccine research. Of the many different types of immunopotentiating compounds that have been researched, aquasomes are of considerable promise, because of their potency and adjuvanticity. Aquasomes were prepared by self-assembling of hydroxyapatite by co-precipitation method and thereafter preliminary coated with polyhydroxyl oligomers (cellobiose and trehalose) and subsequently adsorbed with bovine serum albumin (BSA) as a model antigen. The prepared systems were characterized for size, shape, antigen-loading efficiency, in vitro antigen stability, and in vivo performance. BSA-immobilized aquasomes were around 200 nm in diameter and spherical in shape and had approximately 20–30% BSA-loading efficiency. The immunological activity of the formulated aquasomes was compared with plain BSA and better results were observed. Studies also indicated that aquasome formulations could elicit combined T-helper 1 (Th1) and Th2 immune response.


Anti-inflammatory & anti-allergy agents in medicinal chemistry | 2008

Biodegradable Polymer Based Particulate Carrier(s) for the Delivery of Proteins and Peptides

Neeraj Mishra; Amit K. Goyal; Kapil Khatri; Bhuvaneshwar Vaidya; Rishi Paliwal; Shivani Rai; Abhinav Mehta; Shailja Tiwari; Shiva Vyas; Suresh P. Vyas

Construction of safe and effective delivery systems for proteins and peptides is demand of current clinical practices. Biodegradable polymers based particulates carriers fulfill much of the requirement in this applicable field. Number of marketed products related to biodegradable polymers encapsulating proteins is increasing. However, it has not achieved its proper place since problems related to the protein processing and stabilization limits the scientific community. In this present review we have summarized various aspects related to the formulation and processing of biodegradable polymerized microparticles/ nanoparticles for delivery of therapeutic proteins and peptides. A brief introduction of biodegradable polymers has been incorporated for readers benefit. In addition, biodegradable polymers based carriers designed for vaccine delivery has been incorporated in detail. Functionalized biodegradable carrier(s) for site specific delivery of proteineous matter has also been discussed.

Collaboration


Dive into the Abhinav Mehta's collaboration.

Top Co-Authors

Avatar

Amit K. Goyal

Central Electronics Engineering Research Institute

View shared research outputs
Top Co-Authors

Avatar

Suresh P. Vyas

Dr. Hari Singh Gour University

View shared research outputs
Top Co-Authors

Avatar

Kapil Khatri

Council of Scientific and Industrial Research

View shared research outputs
Top Co-Authors

Avatar

Ankur Bhardwaj

Punjab Technical University

View shared research outputs
Top Co-Authors

Avatar

Bhuvaneshwar Vaidya

Keck Graduate Institute of Applied Life Sciences

View shared research outputs
Top Co-Authors

Avatar

Rishi Paliwal

National Centre for Medium Range Weather Forecasting

View shared research outputs
Top Co-Authors

Avatar

Prem N. Gupta

Banaras Hindu University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge